Bone Metastases and Bone Loss Medical Treatment in Prostate Cancer Patients

Authors

  • Ferry Safriadi Department of Urology, Faculty of Medicine, Padjajaran University - Hasan Sadikin Hospital Bandung, Indonesia

Abstract

Prostate cancer is a malignancy in urology with the highest incidence metastasize to the bone up to 70%. The incidence of skeletal related event (SRE) by 46.1% such as severe pain, pathologic fractures, spinal compression syndrome and hypercalcemia, with a consequence of higher inpatient care and worsen the patient’s prognosis. Androgen deprivation therapy (ADT) as a metastatic prostate cancer treatment itself causes an osteopenia or osteoporosis. Bisphosphonate inhibits normal and pathologic osteoclast-mediated bone resorption by several mechanisms. Denosumab is the latest treatment option in bone metastases. Multi-study shows the efficacy of denosumab is better than zoledronic acid for SRE prevention. Adverse events between denosumab and bisphosphonate are comparable. Key words: prostate cancer, bone metastases, bone loss, treatment.

Downloads

Published

2013-01-01

How to Cite

Safriadi, F. (2013). Bone Metastases and Bone Loss Medical Treatment in Prostate Cancer Patients. Acta Medica Indonesiana, 45(1). Retrieved from http://actamedindones.org/index.php/ijim/article/view/126

Issue

Vol. 45 No. 1 (2013)

Section

CLINICAL PRACTICE

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.